Neurocrine initiates Phase 1 study of NBIP-01435

Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia. In April 2021, Neurocrine entered into a research collaboration with Sentia Medical Sciences, Inc., for the discovery of novel peptide CRF receptor antagonists, including NBIP-01435, for which Neurocrine has exclusive rights to develop and commercialize.